PhD Madiha Derouazi
CEO, Speransa Therapeutics
Madiha has been working on vector engineering and vaccine design for over 18 years. She has a strong background in applied molecular and cellular biotechnology, in virology and in immunology, with research interests at the interface of fundamental and translational research, the so-called bench-to-bedside. She especially focuses on immune stimulation and immune modulation, both in the oncology and infectious disease fields. Madiha holds a PhD in Biotechnology from the Ecole Polytechnique Fédérale de Lausanne (EPFL), and a Master in Biotechnology Engineering from the University of Technology of Berlin. Madiha is also the Scientific Founder of AMAL Therapeutics, a Swiss biotech company developing first-in-class therapeutic cancer vaccines. She designed and characterized a CPP-based multi-epitopic cancer vaccine in the Laboratory of Tumour Immunology of the University of Geneva, which is the basis of the KISIMA proprietary vaccine platform.